MYDECINE INNOVATNS GP INC - MYCOF STOCK NEWS

Mydecine Innovations Group (NEO: MYCO, OTC: MYCOF) will participate in Microdose’s Wonderland: Miami on November 8-9, 2021, at the Adrienne Arsht Center in Miami, FL. This biotechnology company focuses on innovative treatments for mental health disorders and addiction, including PTSD, depression, and anxiety. Mydecine aims to bridge the gap in mental healthcare by developing novel therapeutics using advanced technology and drug development practices. Interested parties can schedule one-on-one meetings with management for further discussions.

Mydecine Innovations Group (NEO: MYCO, OTC: MYCOF) has synthesized a novel psilocin analogue aimed at enhancing safety and efficacy for medical use. This addition to their library of patent-pending tryptamines aligns with their strategy to improve drug development candidates. The synthesis demonstrates their capability in drug chemistry and supports their AI-driven drug discovery program, developed in collaboration with Applied Pharmaceutical Innovation. This advance strengthens their pipeline for psychedelic-based therapeutics targeting mental health issues.

Mydecine Innovations Group (NEO: MYCO, OTC: MYCOF) has announced CEO Josh Bartch will present at the KCSA Psychedelics Investor Conference on October 14, 2021, at 1:30 p.m. ET. The event will be hosted on VirtualInvestorConferences.com from October 13-14. Interested participants can register for attendance here. Mydecine is a biopharmaceutical company focused on treating mental health disorders and addiction, dedicated to developing innovative therapeutics using psychedelic therapy.

Mydecine Innovations Group (MYCOF) has announced its lead drug candidate, MYCO-001, will be supplied for a groundbreaking multi-site smoking cessation study at Johns Hopkins University, New York University, and the University of Alabama Birmingham. Funded by a NIDA grant, this is the first U.S. government-backed study of a psychedelic for therapeutic use in over 50 years. The Phase 2/3 trial, projected to start in Q1 2022, aims to gather further efficacy and safety data for MYCO-001, which previously showed six-month abstinence rates as high as 80% in earlier trials.

Mydecine Innovations Group (OTC: MYCOF) has successfully completed the spin-out of its U.S. cannabis assets into ALT House Cannabis Inc. (SpinCo). Each shareholder received one new Mydecine share and 0.010300 SpinCo shares. The spin-out aims to comply with NASDAQ listing requirements by removing an obstacle presented by U.S. cannabis assets. Mydecine will now focus on developing end-to-end mental health treatments, leveraging its R&D capabilities for safe, FDA-approved solutions, while SpinCo aims to monetize its cannabis projects. New shares began trading on October 1, 2021.

Mydecine Innovations Group (MYCOF) has announced that its spin-out transaction with ALT House Cannabis Inc. has received shareholder approval, with 99.939% voting in favor during the annual meeting on September 20, 2021. The Supreme Court of British Columbia granted final approval on September 24, 2021. If Aequitas Neo Exchange's acceptance and other conditions are met, the spin-out is expected to complete by October 1, 2021. Additionally, six directors were elected, with David Joshua Bartch remaining as CEO. The company focuses on psychedelic-assisted therapeutics and has a cGMP certified manufacturing facility.

Mydecine Innovations Group (MYCOF) has filed a final patent application for its lead drug candidate, MYCO-003, aimed at treating anxiety and PTSD. The drug combines a serotonin agonist with a serotonin-releasing agent, showing potential in reducing anxiety during therapy compared to traditional psilocybin treatments. Positive preclinical data supports its continued development, with expectations of enhancing treatment efficacy and safety for patients suffering from severe anxiety and PTSD, according to company executives.

Mydecine Innovations Group (NEO:MYCO) has partnered with Dr. Matthew Johnson of Johns Hopkins University for a phase 2/3 clinical trial evaluating MYCO-001 in smoking cessation. The study, launching in Q1 2022, aims to assess the efficacy of MYCO-001 alongside a structured treatment program. This operationally seamless clinical trial design allows for adjustments as data is collected. Previous research highlighted an 80% abstinence rate at six months. Mydecine anticipates breakthrough therapy status for MYCO-001, driven by increasing efficacy rates compared to traditional therapies.

Mydecine Innovations Group (NEO: MYCO, OTC: MYCOF) announced CEO Josh Bartch will present at three upcoming virtual conferences. These include the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where his presentation will be available on-demand from September 13th at 7:00 a.m. ET. He will also participate in the Oppenheimer Fall Healthcare Life Sciences Summit on September 21st, and the Maxim’s Advances in Mental Health Conference on September 22nd, focusing on disruptive trends in mental health.